Advaxis

$0.8431
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0391 (-4.43%) As of 8:52 PM UTC today

Why Robinhood?

You can buy or sell Advaxis and other stocks, options, and ETFs commission-free!

About ADXS

Advaxis, Inc. Common Stock, also called Advaxis, is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. The listed name for ADXS is Advaxis, Inc. Common Stock.

CEO
Kenneth A. Berlin
Employees
18
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
112.71M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
15.55M
High Today
$0.8879
Low Today
$0.821
Open Price
$0.8783
Volume
4.10M
52 Week High
$1.57
52 Week Low
$0.2639

ADXS Earnings

-$1.32
-$0.88
-$0.44
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

FRDM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure